Safety and Tolerability of Open-Labeled Iloperidone in Adolescents
NCT ID: NCT05648591
Last Updated: 2025-03-04
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE4
100 participants
INTERVENTIONAL
2023-05-24
2026-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Tolerability and Pharmacokinetics of Iloperidone in Adolescent Patients
NCT01495169
Safety, Tolerability, and Pharmacokinetics of Iloperidone Depot in Schizophrenic Patients
NCT01348100
Olanzapine Treated Adolescents With Schizophrenia or Bipolar I Disorder
NCT00113594
Study in Adolescents With Schizophrenia or Bipolar Disorder
NCT00982020
Safety and Efficacy of Olanzapine in the Long-term Treatment for Bipolar I Disorder, Depressed
NCT00618748
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Iloperidone
Open-label iloperidone
Iloperidone
oral tablet
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Iloperidone
oral tablet
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patient's parent or legal guardian willing and able to provide consent
* Male or female patients 12 through 17 years of age (inclusive)
* Clinical diagnosis of either schizophrenia or bipolar I disorder
Exclusion Criteria
* A positive test for drugs of abuse
12 Years
17 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Vanda Pharmaceuticals
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Vanda Investigational Site
Little Rock, Arkansas, United States
Vanda Investigational Site
Denver, Colorado, United States
Vanda Investigational Site
Atlanta, Georgia, United States
Vanda Investigational Site
Atlanta, Georgia, United States
Vanda Investigational Site
Decatur, Georgia, United States
Vanda Investigational Site
Cincinnati, Ohio, United States
Vanda Investigational Site
Garfield Heights, Ohio, United States
Vanda Investigational Site
Westlake, Ohio, United States
Vanda Investigational Site
Everett, Washington, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Vanda Pharmaceuticals
Role: primary
Role: primary
Role: primary
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
VP-VYV-683-4101
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.